When the pandemic hit and the world shut down, we knew we must respond. Read about the evolution of the Sal6830 Point of Care PCR System.

Our Response to the COVID-19 Pandemic


MicroGEM Granted Emergency Use Authorization from FDA for Fast Point of Care PCR Covid-19 Saliva Test

Health Canada Authorizes World's First Saliva Point of Care PCR Test to Quickly Detect SARS-CoV-2


Leveraging over $50 million received from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative, MicroGEM pivoted to launch our PCR saliva test for point-of-care detection of SARS-CoV-2.

We rapidly expanded our high-tech manufacturing capacity to over 120,000 square feet of manufacturing space in three different states with production capacity of 4 million COVID-19 tests per month.

Now granted Emergency Use Authorization from the FDA and authorized under Interim Order from Health Canada, the Sal6830 provides 'saliva sample collection to PCR result' at the point of care in under 30 minutes.

Moving the technology from the lab to the point of care is a game changer for molecular diagnostics.  Using non-invasive saliva collection where the person being tested gives a sample (saliva) rather than having it taken from them (swab), it provides the speed of a point of care test with the accuracy of a central lab.

The technology brings together MicroGEM’s ultrafast RT-PCR, patented temperature-driven, enzymatic RNA extraction technology, and viral enrichment to quickly, accurately, and comfortably identify people infected with SARS-CoV-2, capturing whole virus as an indicator of infection. 

Jeff Chapman, President and CEO - Microgem Bio

“MicroGEM is committed to help end this devastating pandemic by ensuring high-quality COVID-19 tests are available for more Americans. We’ve leveraged the technologies currently in our pipeline to create a simple and expedient way to provide highly reliable RT-PCR saliva tests to those who need them.”

Jeff Chapman, President and CEO

Senior Leadership

We’re Proudly Made in America.

With highly automated manufacturing facilities across the country with the production capacity to produce over 4 million tests per month, we are committed to helping people resume their regular activities.

Find out more


We’re Always Looking for Great Talent.

We're explorers and innovators. We're developing cutting-edge molecular biology technologies for use in the field and at the point of care, where and when they are needed.

From the discovery of microorganisms living in the extreme temperatures of Antarctica, MicroGEM has grown into an international biotechnology company:

  • R&D facilities in New Zealand and Virginia
  • Advanced manufacturing facilities in New Hampshire and Utah
  • Staff located throughout the world.

Do you have an interest in infectious diseases or molecular biology? Do you want to help develop technologies to improve the health and well-being of people around the world?

Join us!

Find out more

We’re All About DNA and RNA.

Say goodbye to columns and beads. MicroGEM’s barrier-breaking single-tube approach speeds up extractions, reduces contamination, significantly decreases manual steps, and minimizes loss of DNA and RNA from precious samples.

Our core competency is the ability to efficiently extract DNA and RNA regardless of the sample size.

  • No detergents or chaotropic salts.
  • No harsh chemicals or multiple steps.
  • Just temperature-driven, enzymatic lysis and extraction.

For more information on our extraction technologies, associated research products, and online shop, visit www.microgembio.com.